Skip to content

The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B

Efficacy Comparison Between Two Kind of Chinese Herbal Formulas on Traditional Chinese Medicine Syndromes Among Chronic Hepatitis Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03018821
Enrollment
250
Registered
2017-01-12
Start date
2017-01-31
Completion date
2017-12-31
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Chronic

Brief summary

Although the incidence of Hepatitis B has been decreased a lot recently years, there are still quite a few chronic hepatitis B patients in China. The anti-virus drugs of western medicine such as Entecavir and Tenofovir have been proved effective on decreasing the serum hepatitis B virus (HBV) level, on the other hand, Chinese materia medica showed effective on TCM syndromes of chronic hepatitis B (CHB) such as hypochondriac pain, jaundice and abdominal mass. Besides, the hepatic fibrosis could be delayed after the appropriate treatment of TCM. This study is a multicenter, randomized, open label, parallel group clinical trial to evaluate the efficacy of two different traditional Chinese medicine (TCM) herbal treatment on chronic hepatitis B.

Interventions

DRUGStandard - Yinchengao Decoction plus Ganlu Detoxification Pill

Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.

Western drug for anti-HBV such as Entecavir and Tenofovir

DRUGStandard - Ge Xia Zhu Yu Decoction

Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.

DRUGAdvanced - Supplemented Taohong Huazhuo Decoction

Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.

DRUGStandard - Chaihu Shugan San

Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.

DRUGAdvanced - Soothe the liver and regulate qi Decoction

Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.

DRUGStandard - Xiaoyao powder

Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.

DRUGAdvanced - Supplemented Ganbi Decoction

Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.

DRUGStandard - Yiguan Decoction

Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.

DRUGAdvanced - Supplemented Zimu Dan

Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.

DRUGStandard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus

Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.

DRUGAdvanced - Guifu Erxian Decoction

Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.

DRUGAdvanced - Supplemented Ganji Decoction

Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.

Sponsors

Xi'an Traditional Medicine Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18\<=age at treatment\<=65 years old * Was diagnosed as chronic hepatitis B (ICD10:K73.901) and one of the following Chinese syndromes: hypochondriac pain (TCD:BNG010), jaundice(TCD:BNG020) or abdominal mass (TCD:BNG040).

Exclusion criteria

* Combined with other virus hepatitis or alcoholic hepatitis * Combined with autoimmune disease * Combined with liver cancer or cirrhosis * Combined with severe hepatitis with or without complications * Combined with unstable cardio-cerebrovascular disease * Combined with severe lung, kidney, endocrine system, nervous system and hematological system diseases * Combined with Tuberculosis * Chronic hepatitis patients with ongoing INF treatment * Woman with pregnancy or breasting feeding * Mental disorder and can not express self clearly * Cannot speak Chinese * Allergic constitution or allergy to multiple drugs * Refuse to enroll into the study

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medicine symptom scaleChange of TCM symptom scale between baseline and sixth months of treatment

Secondary

MeasureTime frameDescription
The change of liver fibrosisChnage of liver fibrosis between baseline and 6th months of treatmentUse change of FibroScan measurement of liver between baseline and 6th months of treatment to express the change of liver fibrosis
Overall effectiveness of treatment defined by the guidelines for prevention and treatment of chronic hepatitis BOverall effectiveness of treatment between baseline and 6th months of treatmentTreatments were completely effective, partially effective or not effective after treatment. Complete effective: Alanine aminotransferase normal, HBV DNA, HBeAg and HBsAg are negative Partially effective: Alanine aminotransferase normal, HBV DNA, HBeAg are negative and HBsAg stay positive Not effective: Did not reach any one of what are listed above.

Countries

China

Contacts

Primary ContactJianmei Hao, MD
12479088@qq.com86-29-89626651

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026